Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205436 · ClinicalTrials.gov registry record · NA
Affinity Prospective Diabetic Foot Trial Crossover Group
A NA study, sponsored by Organogenesis.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT03205436: Completed NA study, sponsored by Organogenesis.
NCT03205436 is a NA study that has completed, run by Organogenesis. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03205436, a NA study, has completed, sponsored by Organogenesis.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is an extension of the randomized controlled trial NT-DFU-AFF-01. Subjects that were randomized to the Standard of Care group will be able to crossover to the NT-DFU-AFF-02 trial and receive Affinity fHSAM if certain criteria are met.
Interventions
- OTHER Affinity human amniotic membrane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2019-08-15 |
| Phase | NA |
What the finished NCT03205436 record still lists
NCT03205436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Affinity human amniotic membrane is the first listed.
NCT03205436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03205436 about?
NCT03205436 is a clinical study titled "Affinity Prospective Diabetic Foot Trial Crossover Group". This study is an extension of the randomized controlled trial NT-DFU-AFF-01. Subjects that were randomized to the Standard of Care group will be able to crossover to the NT-DFU-AFF-02 trial and receive Affinity fHSAM if certain criteria are met.
What is the current status of trial NCT03205436?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2017-05-01. Estimated completion is 2019-08-15.
What interventions are being tested in trial NCT03205436?
The interventions under investigation include: Affinity human amniotic membrane (OTHER).
Who is sponsoring clinical trial NCT03205436?
This trial is sponsored by Organogenesis, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03205436's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI